AN-019

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAN-019
Drug Alias NameNRC-AN-019NRC-019AN-019
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myeloid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNatco Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNatco Pharma
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid

Other Information

ATC CodeN/A
Related LinksN/A